Purchase this article with an account.
Simona Degli Esposti, Pearse A. Keane, Fred K. Chen, Lyndon Da Cruz, Adnan Tufail, Praveen J. Patel; Spectral-domain Optical Coherence Tomography Outcomes of Ranibizumab Therapy for Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):143.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report spectral-domain optical coherence tomography (SDOCT) outcomes of ranibizumab therapy for neovascular age-related macular degeneration (nAMD) in clinical practice.
A retrospective review of SDOCT imaging of 100 eyes of 100 consecutive patients receiving ranibizumab therapy for nAMD. Patients were treated with 3 injections with further treatment based on signals of disease activity. Images were read by an experienced ophthalmologist with an assessment of abnormalities of retinal morphology at baseline, after 3 injections and after 12 month follow-up. In addition, automated retinal thickness measurements were noted at these time points as were visual acuity outcomes.
One hundred eyes of 100 consecutive patients with nAMD were included in the analysis with a mean (±SD) age of 79.3 (± 9.9) years. Subretinal/intraretinal fluid was present in 90.1% of eyes at baseline, 63.3% after 3 injections and 68.9% at one year. Subretinal tissue was present in 37.6% at baseline, 46.5% after 3 injections and 52.7% of the eyes at 1 year. At baseline mean central macular thickness was 281.4 µm, 232.0 µm after 3 injections and 241.7 µm at 1 year. The mean gain in visual acuity from baseline was +6.1 ETDRS letters after 3 injections and + 3.8 letters at 1 year.
In this work we report SDOCT changes in retinal morphology and thickness with ranibizumab therapy in a "real-world" clinical cohort of patients with nAMD. Therapy led to a reduction in the proportion of patients with macular fluid with improvement in visual acuity outcomes. However macular fluid persisted in over half of the cohort suggesting persistent or recurrent disease activity and the need for ongoing therapy.
This PDF is available to Subscribers Only